title: Intravitreal bevacizumab for retinal capillary haemangioma: longterm results.
authors.forename: Thomas
authors.initials: T
authors.lastname: Ach
authors.forename: Dorothea
authors.initials: D
authors.lastname: Thiemeyer
authors.forename: Alexandra Eva
authors.initials: AE
authors.lastname: Hoeh
authors.forename: Karen Beate
authors.initials: KB
authors.lastname: Schaal
authors.forename: Stefan
authors.initials: S
authors.lastname: Dithmar
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005500:Follow-Up Studies; D018324:Hemangioma, Capillary / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007267:Injections; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000209:etiology; D019233:Retreatment; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body; D006623:von Hippel-Lindau Disease / Q000150:complications / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab